Evaxion
Copenhagen
About Evaxion
Evaxion is an AI-driven biotech company that uses its proprietary AI-Immunology™ platform to identify vaccine targets across cancer and infectious diseases. Its clinical programs include a personalized cancer vaccine in Phase II, and preclinical candidates targeting Staphylococcus aureus, gonorrhea, CMV, and more.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $114.2M
- Funding stage: IPO
- Last round: Post-IPO Equity (Oct 2025)
- Ticker: nasdaq:EVAX
- Website: evaxion.ai
- Phone: [email protected]
Industries & Categories
Artificial Intelligence (AI), Biotechnology
Social Profiles
Canonical: https://fsome.com/organization/evaxion-27575 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.